- Study type: Randomised Clinical Trial, Prevention
- Study type descriptors: Randomised controlled trial, Single centre
- Objective: To evaluate the safety and immune response of a new nasal COVID-19 vaccine, using various vaccine doses and administration methods
- Number of participants enrolled: 40
- Study enrolling from to
- Study includes follow-up for 28 days
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Vaccination
- Nasal vaccine
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to